[
  {
    "ts": null,
    "headline": "Novavax slides after RFK Jr. casts doubts about COVID vaccine",
    "summary": "Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay. The Secretary of Health and Human Services pointed to the vaccine’s single-antigen composition as the reason for the push back, adding that the FDA is “shifting our priorities to multiple-antigen vaccines.” SHIFTING PRIORITIES: The Food and Drug Administration is sitting on the decision to grant full approval for Novavax COVID-19 shot. In an interview wit",
    "url": "https://finnhub.io/api/news?id=9b6d2893f2c9dde9ea83a37f9f799ebc6249324346fe177915277c3aa29ae0f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744384814,
      "headline": "Novavax slides after RFK Jr. casts doubts about COVID vaccine",
      "id": 133880835,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay. The Secretary of Health and Human Services pointed to the vaccine’s single-antigen composition as the reason for the push back, adding that the FDA is “shifting our priorities to multiple-antigen vaccines.” SHIFTING PRIORITIES: The Food and Drug Administration is sitting on the decision to grant full approval for Novavax COVID-19 shot. In an interview wit",
      "url": "https://finnhub.io/api/news?id=9b6d2893f2c9dde9ea83a37f9f799ebc6249324346fe177915277c3aa29ae0f0"
    }
  }
]